FDA Grants Hemispherx Biopharma Extension for Pending NDA for the Treatment of Chronic Fatigue Syndrome

January 11, 2012
Hemispherx Biopharma announced that the FDA granted an extension for it to modify its NDA in response to a Complete Response Letter received November 25, 2009 for the Chronic Fatigue Syndrome therapeutic indication.
Yahoo! Finance